A new class of isothiocyanate-based irreversible inhibitors of macrophage migration inhibitory factor

Biochemistry

Volumn 48, Issue 41, 2009, Pages 9858-9870

  Ouertatani Sakouhi, Hajer ^a   El Turk, Farah ^a   Fauvet, Bruno ^a   Roger, Thierry ^b   Roy, Didier Le ^b   Karpinar, Damla Pinar ^c   Leng, Lin ^d   Bucala, Richard ^d   Zweckstetter, Markus ^c   Calandra, Thierry ^b   Lashuel, Hilal A ^a  

^a EPFL   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c MAX PLANCK INSTITUTE FOR BIOPHYSICAL CHEMISTRY   (Germany)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVE SITE; AKT PHOSPHORYLATION; ANALYTICAL ULTRACENTRIFUGATION; AUTOIMMUNE DISEASE; BENZYL ISOTHIOCYANATE; BIOLOGICAL ACTIVITIES; CATALYTIC ACTIVITY; CONFORMATIONAL STATE; IN-VIVO; ISOTHIOCYANATES; MECHANISM OF ACTION; MIGRATION INHIBITORY FACTORS; N-TERMINALS; NEUTRALIZING ANTIBODIES; NEW OPPORTUNITIES; NMR STUDIES; PROINFLAMMATORY CYTOKINES; PROLINE RESIDUES; QUATERNARY STRUCTURE; RECEPTOR BINDING; STRUCTURAL STUDIES; TAUTOMERASE; TERTIARY STRUCTURES; THERAPEUTIC STRATEGY;

BINDING SITES; CATALYST ACTIVITY; CENTRIFUGATION; ELECTROCHEMICAL SENSORS; MACROPHAGES; MODULATION; OLIGOMERIZATION; THERMODYNAMIC STABILITY;

BIOACTIVITY;

BENZYL ISOTHIOCYANATE; ISOTHIOCYANIC ACID; MACROPHAGE MIGRATION INHIBITION FACTOR;

AMINO TERMINAL SEQUENCE; ARTICLE; BIOCHEMISTRY; BIOLOGICAL ACTIVITY; BIOPHYSICS; ENZYME INACTIVATION; LIGHT SCATTERING; NUCLEAR MAGNETIC RESONANCE; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN QUATERNARY STRUCTURE; PROTEIN SYNTHESIS; RECEPTOR BINDING; THERMODYNAMICS; ULTRACENTRIFUGATION;

AUTOIMMUNE DISEASES; CHROMATOGRAPHY, GEL; CYTOKINES; GLUCOCORTICOIDS; HUMANS; INFLAMMATION; INTRAMOLECULAR OXIDOREDUCTASES; ISOTHIOCYANATES; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MODELS, MOLECULAR; PHOSPHORYLATION; PROTEIN CONFORMATION; SCATTERING, RADIATION; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 70350062352     PISSN: 00062960     EISSN: None     Source Type: Journal    
DOI: 10.1021/bi900957e     Document Type: Article

References (59)

1. Calandra, T., and Roger, T. (2003) Macrophage migration inhibitory factor: A regulator of innate immunity. Nat. Rev. Immunol. 3, 791-800.
2. Calandra, T., Bernhagen, J., Metz, C. N., Spiegel, L. A., Bacher, M., Donnelly, T., Cerami, A., and Bucala, R. (1995) MIF as a glucocorticoid-induced modulator of cytokine production. Nature 377, 68-71.
3. Mitchell, R. A., Metz, C. N., Peng, T., and Bucala, R. (1999) Sustained mitogen-activated protein kinase(MAPK) and cytoplasmic phospholipase A2 activation by macrophage migration inhibitory factor (MIF). Regulatory role in cell proliferation and glucocorticoid action. J. Biol. Chem. 274, 18100-18106.
4. Hudson, J. D., Shoaibi, M. A., Maestro, R., Carnero, A., Hannon, G. J., and Beach, D. H. (1999) A proinflammatory cytokine inhibits p53 tumor suppressor activity. J. Exp. Med. 190, 1375-1382.
5. Fingerle-Rowson, G., Petrenko, O., Metz, C. N., Forsthuber, T. G., Mitchell, R., Huss, R., Moll, U., Muller, W., and Bucala, R. (2003) The p53-dependent effects of macrophage migration inhibitory factor revealed by gene targeting. Proc.Natl.Acad. Sci. U.S.A. 100, 9354-9359.
6. Lue, H., Kapurniotu, A., Fingerle-Rowson, G., Roger, T., Leng, L., Thiele, M., Calandra, T., Bucala, R., and Bernhagen, J. (2006) Rapid and transient activation of the ERK MAPK signalling path way bymacrophagemigration inhibitory factor (MIF) and dependence on JAB1/CSN5 and Src kinase activity. Cell. Signalling 18, 688-703. (Pubitemid 43113299)
7. Morand, E. F., Leech, M., Weedon, H., Metz, C., Bucala, R., and Smith, M. D. (2002) Macrophage migration inhibitory factor in rheumatoid arthritis: Clinical correlations. Rheumatology (Oxford, U.K.) 41, 558-562. (Pubitemid 34567187)
8. Radstake, T. R., Nabbe, K. C., Wenink, M. H., Roelofs, M. F., Oosterlaar, A., van Lieshout, A. W., Barrera, P., van Lent, P. L., and van den Berg, W. B. (2005) Dendritic cells from patients with rheumatoid arthritis lack the interleukin 13 mediated increase of Fc gamma RII expression, which has clear functional consequences. Ann. Rheum. Dis. 64, 1737-1743.
9. Lan, H. Y., Yang, N., Nikolic-Paterson, D. J., Yu, X. Q., Mu, W., Isbel, N. M., Metz, C. N., Bucala, R., and Atkins, R. C. (2000) Expression of macrophage migration inhibitory factor in human glomerulonephritis. Kidney Int. 57, 499-509. (Pubitemid 30430641)
10. Brown, F. G., Nikolic-Paterson, D. J., Hill, P. A., Isbel, N. M., Dowling, J., Metz, C. M., and Atkins, R. C. (2002) Urine macrophage migration inhibitory factor reflects the severity of renal injury in human glomerulonephritis. J. Am. Soc. Nephrol. 13 (Suppl. 1), S7-S13.
11. Yabunaka, N., Nishihira, J., Mizue, Y., Tsuji, M., Kumagai, M., Ohtsuka, Y., Imamura, M., and Asaka, M. (2000) Elevated serum content of macrophage migration inhibitory factor in patients with type 2 diabetes. Diabetes Care 23, 256-258. (Pubitemid 30071036)
12. Verschuren, L., Kooistra, T., Bernhagen, J., Voshol, P. J., Ouwens, D. M., van Erk, M., de Vries-van der Weij, J., Leng, L., van Bockel, J. H., van Dijk, K. W., Fingerle-Rowson, G., Bucala, R., and Kleemann, R. (2009) MIF Deficiency Reduces Chronic Inflammation in White Adipose Tissue and Impairs the Development of Insulin Resistance, Glucose Intolerance, and Associated Atherosclerotic Disease. Circ. Res. 105, 99-107.
13. de Jong, Y. P., Abadia-Molina, A. C., Satoskar, A. R., Clarke, K., Rietdijk, S. T., Faubion, W. A., Mizoguchi, E., Metz, C. N., Alsahli, M., ten Hove, T., Keates, A. C., Lubetsky, J. B., Farrell, R. J., Michetti, P., van Deventer, S. J., Lolis, E., David, J. R., Bhan, A. K., and Terhorst, C. (2001) Development of chronic colitis is dependent on the cytokine MIF. Nat. Immunol. 2, 1061-1066.
14. Bernhagen, J., Calandra, T., Mitchell, R. A., Martin, S. B., Tracey, K. J., Voelter, W., Manogue, K. R., Cerami, A., and Bucala, R. (1993) MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature 365, 756-759. (Pubitemid 23339882)
15. Roger, T., Glauser, M. P., and Calandra, T. (2001) Macrophage migration inhibitory factor (MIF) modulates innate immune responses induced by endotoxin and Gram-negative bacteria. J. Endotoxin Res. 7, 456-460. (Pubitemid 34048531)
16. Beishuizen, A., Thijs, L. G., Haanen, C., and Vermes, I. (2001) Macrophage migration inhibitory factor and hypothalamo-pituitary-adrenal function during critical illness. J. Clin. Endocrinol. Metab. 86, 2811-2816.
17. Emonts, M., Sweep, F. C., Grebenchtchikov, N., Geurts-Moespot, A., Knaup, M., Chanson, A. L., Erard, V., Renner, P., Hermans, P. W., Hazelzet, J. A., and Calandra, T. (2007) Association between high levels of blood macrophage migration inhibitory factor, inappropriate adrenal response, and early death in patients with severe sepsis. Clin. Infect. Dis. 44, 1321-1328.
18. Arjona, A., Foellmer, H. G., Town, T., Leng, L., McDonald, C., Wang, T., Wong, S. J., Montgomery, R. R., Fikrig, E., and Bucala, R. (2007) Abrogation of macrophage migration inhibitory factor decreases West Nile virus lethality by limiting viral neuroinvasion. J. Clin. Invest. 117, 3059-3066.
19. Donnelly, S. C., Haslett, C., Reid, P. T., Grant, I. S., Wallace, W. A., Metz, C. N., Bruce, L. J., and Bucala, R. (1997) Regulatory role for macrophage migration inhibitory factor in acute respiratory distress syndrome. Nat. Med. 3, 320-323.
20. Mizue, Y., Ghani, S., Leng, L., McDonald, C., Kong, P., Baugh, J., Lane, S. J., Craft, J., Nishihira, J., Donnelly, S. C., Zhu, Z., and Bucala, R. (2005) Role for macrophage migration inhibitory factor in asthma. Proc. Natl. Acad. Sci. U.S.A. 102, 14410-14415.
21. Mitchell, R. A. (2004) Mechanisms and effectors of MIF-dependent promotion of tumourigenesis. Cell. Signalling 16, 13-19.
22. Meyer-Siegler, K. L., Vera, P. L., Iczkowski, K. A., Bifulco, C., Lee, A., Gregersen, P. K., Leng, L., and Bucala, R. (2007) Macrophage migration inhibitory factor (MIF) gene polymorphisms are associated with increased prostate cancer incidence. Genes Immun. 8, 646-652. (Pubitemid 350238434)
23. Bucala, R., and Donnelly, S. C. (2007) Macrophage migration inhibitory factor: A probable link between inflammation and cancer. Immunity 26, 281-285. (Pubitemid 46413914)
24. Rosengren, E., Bucala, R., Aman, P., Jacobsson, L., Odh, G., Metz, C. N., and Rorsman, H. (1996) The immunoregulatory mediator macrophage migration inhibitory factor (MIF) catalyzes a tautomerization reaction. Mol. Med. 2, 143-149.
25. Lolis, E., and Bucala, R. (1996) Crystal structure of macrophage migration inhibitory factor (MIF), a glucocorticoid-induced regulator of cytokine production, reveals a unique architecture. Proc. Assoc. Am. Physicians 108, 415-419.
26. Bendrat, K., Al-Abed, Y., Callaway, D. J., Peng, T., Calandra, T., Metz, C. N., and Bucala, R. (1997) Biochemical and mutational investigations of the enzymatic activity of macrophage migration inhibitory factor. Biochemistry 36, 15356-15362. (Pubitemid 27528002)
27. Stamps, S. L., Fitzgerald, M. C., and Whitman, C. P. (1998) Characterization of the role of the amino-terminal proline in the enzymatic activity catalyzed by macrophage migration inhibitory factor. Biochemistry 37, 10195-10202. (Pubitemid 28366375)
28. Al-Abed, Y., Dabideen, D., Aljabari, B., Valster, A., Messmer, D., Ochani, M., Tanovic, M., Ochani, K., Bacher, M., Nicoletti, F., Metz, C., Pavlov, V. A., Miller, E. J., and Tracey, K. J. (2005) ISO-1 binding to the tautomerase active site of MIF inhibits its pro-inflammatory activity and increases survival in severe sepsis. J. Biol. Chem. 280, 36541-36544.
29. Crichlow, G. V., Cheng, K. F., Dabideen, D., Ochani, M., Aljabari, B., Pavlov, V. A., Miller, E. J., Lolis, E., and Al-Abed, Y. (2007) Alternative chemical modifications reverse the binding orientation of a pharmacophore scaffold in the active site of macrophage migration inhibitory factor. J. Biol. Chem. 282, 23089-23095.
30. Morand, E. F. (2005) New therapeutic target in inflammatory disease: Macrophage migration inhibitory factor. Intern. Med. J. 35, 419-426.
31. Senter, P. D., Al-Abed, Y., Metz, C. N., Benigni, F., Mitchell, R. A., Chesney, J., Han, J., Gartner, C. G., Nelson, S. D., Todaro, G. J., and Bucala, R. (2002) Inhibition of macrophage migration inhibitory factor (MIF) tautomerase and biological activities by acetaminophen metabolites. Proc. Natl. Acad. Sci. U.S.A. 99, 144-149.
32. Lubetsky, J. B., Dios, A., Han, J., Aljabari, B., Ruzsicska, B., Mitchell, R., Lolis, E., and Al-Abed, Y. (2002) The tautomerase active site of macrophage migration inhibitory factor is a potential target for discovery of novel anti-inflammatory agents. J. Biol. Chem. 277, 24976-24982.
33. Dios, A., Mitchell, R. A., Aljabari, B., Lubetsky, J., O'Connor, K., Liao, H., Senter, P. D., Manogue, K. R., Lolis, E., Metz, C., Bucala, R., Callaway, D. J., and Al-Abed, Y. (2002) Inhibition of MIF bioactivity by rational design of pharmacological inhibitors of MIF tautomerase activity. J. Med. Chem. 45, 2410-2416.
34. Dabideen, D. R., Cheng, K. F., Aljabari, B., Miller, E. J., Pavlov, V. A., and Al-Abed, Y. (2007) Phenolic hydrazones are potent inhibitors of macrophage migration inhibitory factor proinflammatory activity and survival improving agents in sepsis. J. Med. Chem. 50, 1993-1997.
35. Bernhagen, J., Mitchell, R. A., Calandra, T., Voelter, W., Cerami, A., and Bucala, R. (1994) Purification, bioactivity, and secondary structure analysis of mouse and human macrophage migration inhibitory factor (MIF). Biochemistry 33, 14144-14155. (Pubitemid 24382359)
36. Philo, J. S., Yang, T. H., and LaBarre, M. (2004) Re-examining the oligomerization state of macrophage migration inhibitory factor (MIF) in solution. Biophys. Chem. 108, 77-87.
37. Delaglio, F., Grzesiek, S., Vuister, G. W., Zhu, G., Pfeifer, J., and Bax, A. (1995) NMRPipe: A multidimensional spectral processing system based on UNIX pipes. J. Biomol. NMR 6, 277-293.
38. Muhlhahn, P., Bernhagen, J., Czisch, M., Georgescu, J., Renner, C., Ross, A., Bucala, R., and Holak, T. A. (1996) NMR characterization of structure, backbone dynamics, and glutathione binding of the human macrophage migration inhibitory factor (MIF). Protein Sci. 5, 2095-2103. (Pubitemid 26347745)
39. Grzesiek, S., Stahl, S. J., Wingfield, P. T., and Bax, A. (1996) The CD4 determinant for downregulation by HIV-1 Nef directly binds to Nef. Mapping of the Nef binding surface by NMR. Biochemistry 35, 10256-10261.
40. Leng, L., Metz, C. N., Fang, Y., Xu, J., Donnelly, S., Baugh, J., Delohery, T., Chen, Y., Mitchell, R. A., and Bucala, R. (2003) MIF signal transduction initiated by binding to CD74. J. Exp. Med. 197, 1467-1476.
41. Meyer, D. J., Crease, D. J., and Ketterer, B. (1995) Forward and reverse catalysis and product sequestration by human glutathione Stransferases in the reaction of GSH with dietary aralkyl isothiocyanates. Biochem. J. 306 (Part 2), 565-569.
42. Ralat, L. A., and Colman, R. F. (2004) Glutathione S-transferase Pi has at least three distinguishable xenobiotic substrate sites close to its glutathione-binding site. J. Biol. Chem. 279, 50204-50213.
43. El-Turk, F., Cascella, M., Ouertatani-Sakouhi, H., Narayanan, R. L., Leng, L., Bucala, R., Zweckstetter, M., Rothlisberger, U., and Lashuel, H. A. (2008) The Conformational Flexibility of the Carboxy Terminal Residues 105-114 Is a Key Modulator of the Catalytic Activity and Stability of Macrophage Migration Inhibitory Factor. Biochemistry 47, 10740-10756.
44. Swope, M. D., Sun, H. W., Klockow, B., Blake, P., and Lolis, E. (1998) Macrophage migration inhibitory factor interactions with glutathione and S-hexylglutathione. J. Biol. Chem. 273, 14877-14884.
45. Shi, X., Leng, L., Wang, T., Wang, W., Du, X., Li, J., McDonald, C., Chen, Z., Murphy, J. W., Lolis, E., Noble, P., Knudson, W., and Bucala, R. (2006) CD44 is the signaling component of the macrophage migration inhibitory factor-CD74 receptor complex. Immunity 25, 595-606. (Pubitemid 44529040)
46. Cournia, Z., Leng, L., Gandavadi, S., Du, X., Bucala, R., and Jorgensen, W. L. (2009) Discovery of human macrophage migration inhibitory factor (MIF)-CD74 antagonists via virtual screening. J. Med. Chem. 52, 416-424.
47. Kamir, D., Zierow, S., Leng, L., Cho, Y., Diaz, Y., Griffith, J., McDonald, C., Merk, M., Mitchell, R. A., Trent, J., Chen, Y., Kwong, Y. K., Xiong, H., Vermeire, J., Cappello, M., McMahon-Pratt, D., Walker, J., Bernhagen, J., Lolis, E., and Bucala, R. (2008) A Leishmania ortholog of macrophage migration inhibitory factor modulates host macrophage responses. J. Immunol. 180, 8250-8261.
48. Lue, H., Thiele, M., Franz, J., Dahl, E., Speckgens, S., Leng, L., Fingerle-Rowson, G., Bucala, R., Luscher, B., and Bernhagen, J. (2007) Macrophage migration inhibitory factor (MIF) promotes cell survival by activation of the Akt pathway and role for CSN5/JAB1 in the control of autocrine MIF activity. Oncogene 26, 5046-5059. (Pubitemid 47206949)
49. Golubkov, P. A., Johnson, W. H., Jr., Czerwinski, R. M., Person, M. D., Wang, S. C., Whitman, C. P., and Hackert, M. L. (2006) Inactivation of the phenylpyruvate tautomerase activity of macrophage migration inhibitory factor by 2-oxo-4-phenyl-3-butynoate. Bioorg. Chem. 34, 183-199.
50. Winner, M., Meier, J., Zierow, S., Rendon, B. E., Crichlow, G. V., Riggs, R., Bucala, R., Leng, L., Smith, N., Lolis, E., Trent, J. O., and Mitchell, R. A. (2008) A novel, macrophage migration inhibitory factor suicide substrate inhibits motility and growth of lung cancer cells. Cancer Res. 68, 7253-7257.
51. Higdon, J. V., Delage, B., Williams, D. E., and Dashwood, R. H. (2007) Cruciferous vegetables and human cancer risk: Epidemiologic evidence and mechanistic basis. Pharmacol. Res. 55, 224-236.
52. Miyoshi, N., Takabayashi, S., Osawa, T., and Nakamura, Y. (2004) Benzyl isothiocyanate inhibits excessive superoxide generation in inflammatory leukocytes: Implication for prevention against inflammation-related carcinogenesis. Carcinogenesis 25, 567-575. (Pubitemid 38499945)
53. Miyoshi, N., Uchida, K., Osawa, T., and Nakamura, Y. (2004) A link between benzyl isothiocyanate-induced cell cycle arrest and apoptosis: Involvement of mitogen-activated protein kinases in the Bcl-2 phosphorylation. Cancer Res. 64, 2134-2142. (Pubitemid 38339464)
54. Mi, L., Gan, N., Cheema, A., Dakshanamurthy, S., Yang, D. C., and Chung, F. L. (2009) Cancer preventive isothiocyanates induce selective degradation of cellular α- and β-tubulins by proteasomes. J. Biol. Chem. 284, 17039-17051.
55. Tsou, M. F., Peng, C. T., Shih, M. C., Yang, J. S., Lu, C. C., Chiang, J. H., Wu, C. L., Lin, J. P., Lo, C., Fan, M. J., and Chung, J. G. (2009) Benzyl isothiocyanate inhibits murine WEHI-3 leukemia cells in vitro and promotes phagocytosis in BALB/c mice in vivo. Leuk. Res. 33, 1505-1511.
56. Fingerle-Rowson, G., Kaleswarapu, D. R., Schlander, C., Kabgani, N., Brocks, T., Reinart, N., Busch, R., Schutz, A., Lue, H., Du, X., Liu, A., Xiong, H., Chen, Y., Nemajerova, A., Hallek, M., Bernhagen, J., Leng, L., and Bucala, R. (2009) A tautomerase-null macrophage migration-inhibitory factor (MIF) gene knock-in mouse model reveals that protein interactions and not enzymatic activity mediate MIF-dependent growth regulation. Mol. Cell. Biol. 29, 1922-1932.
57. Richardson, J. M., Morrison, L. S., Bland, N. D., Bruce, S., Coombs, G. H., Mottram, J. C., and Walkinshaw, M. D. (2009) Structures of Leishmania major orthologues of macrophage migration inhibitory factor. Biochem. Biophys. Res. Commun. 380, 442-448.
58. Merk, M., Baugh, J., Zierow, S., Leng, L., Pal, U., Lee, S. J., Ebert, A. D., Mizue, Y., Trent, J. O., Mitchell, R., Nickel, W., Kavathas, P. B., Bernhagen, J., and Bucala, R. (2009) The Golgi-associated protein p115 mediates the secretion of macrophage migration inhibitory factor. J. Immunol. 182, 6896-6906.
59. Goddard, T. D., and Kneller, D. G. (2004) SPARKY 3, University of California, San Francisco.